Trials / Unknown
UnknownNCT05623930
Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 35 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)
Detailed description
In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | laser acupuncture | In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian |
| OTHER | wet cupping | in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14. |
Timeline
- Start date
- 2022-10-12
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
- First posted
- 2022-11-21
- Last updated
- 2022-11-21
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05623930. Inclusion in this directory is not an endorsement.